Cargando…

A Phase II Study of Pelareorep (REOLYSIN(®)) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival rates of ~18% and 7% respectively. FOLFIRINOX or gemcitabine in combination with nab-paclitaxel are standard treatment options for metastatic disease. However, both regimens are more toxic than gemcitabine alone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahalingam, Devalingam, Goel, Sanjay, Aparo, Santiago, Patel Arora, Sukeshi, Noronha, Nicole, Tran, Hue, Chakrabarty, Romit, Selvaggi, Giovanni, Gutierrez, Andres, Coffey, Matthew, Nawrocki, Steffan T., Nuovo, Gerard, Mita, Monica M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025223/ https://www.ncbi.nlm.nih.gov/pubmed/29799479 http://dx.doi.org/10.3390/cancers10060160

Ejemplares similares

The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2015)

Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer
por: Patel, Sukeshi, et al.
Publicado: (2016)

Review: Oncolytic virotherapy, updates and future directions
por: Fountzilas, Christos, et al.
Publicado: (2017)

Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer
por: Carew, J S, et al.
Publicado: (2013)

Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors
por: Schuelke, Matthew R, et al.
Publicado: (2022)

Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Jaime-Ramirez, Alena C., et al.
Publicado: (2017)

A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma
por: Mahalingam, Devalingam, et al.
Publicado: (2019)

Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis
por: Xie, Renxian, et al.
Publicado: (2023)

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation
por: Carew, Jennifer S, et al.
Publicado: (2010)

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
por: Kelly, Kevin R, et al.
Publicado: (2011)

Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models
por: Mahalingam, Devalingam, et al.
Publicado: (2019)

Individualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus)
por: Carlson, Linda E, et al.
Publicado: (2005)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209
por: Eigl, Bernhard Josef, et al.
Publicado: (2018)

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01
por: Sahai, Vaibhav, et al.
Publicado: (2022)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer
por: Venkatasubbarao, Kolaparthi, et al.
Publicado: (2013)

Case report of prostate ductal adenocarcinoma presenting with hematuria
por: Pawlowski, Jamie, et al.
Publicado: (2018)

Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC)
por: Viveiros, Pedro, et al.
Publicado: (2019)

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas
por: Carew, Jennifer S., et al.
Publicado: (2017)

Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells
por: Khanna, Amit, et al.
Publicado: (2010)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009)

Introduction
por: Nuovo, Gerard J.
Publicado: (2021)

Coexpression analyses
por: Nuovo, Gerard J.
Publicado: (2021)

Gemcitabine and S-1 Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer: A Retrospective Study
por: Mita, Kazuhito, et al.
Publicado: (2010)

Role of Maintenance Gemcitabine in Advanced Carcinoma Gallbladder
por: Sharma, Manish, et al.
Publicado: (2020)

Autophagy: New Insights into Its Roles in Cancer Progression and Drug Resistance
por: Nawrocki, Steffan T., et al.
Publicado: (2020)

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
por: De Souza, Andre, et al.
Publicado: (2020)

Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy
por: Habib, Saffiya, et al.
Publicado: (2021)

Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab
por: Efe, Orhan, et al.
Publicado: (2021)

Autophagy as a target for cancer therapy: new developments
por: Carew, Jennifer S, et al.
Publicado: (2012)

Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy
por: Jones, Trace M., et al.
Publicado: (2020)

Gemcitabine in Recurrent Meningioma
por: Khaddar, Satvik, et al.
Publicado: (2020)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma Patients
por: Tang, Justin Y., et al.
Publicado: (2018)

Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer
por: Mishra, Sweta, et al.
Publicado: (2015)

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx
por: Nuovo, Gerard J., et al.
Publicado: (2020)

The differential immune response in mild versus fatal SARS-CoV2 infection()
por: Suster, David, et al.
Publicado: (2022)

Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade
por: Goel, Sunny, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a6763g76tcuo0qlpgj2k7jl7dd